Check back often to find the latest news on AgeneBio and our pipeline of multiple candidates.
March 11, 2015
AgeneBio scouts deals and dollars ahead of Alzheimer’s PhIII
A small biotech spinout from Johns Hopkins has published its data from a midstage study of a new Alzheimer’s drug that it’s planning to get into a late-stage study. And AgeneBio, founded by Johns Hopkins investigator Michela Gallagher, says the numbers back up its case that they may have something that works against the memory-robbing ailment–a story that the company hopes will deliver the support needed to pursue a Phase III study…
